Abstract P2-05-05: Expression profiling of in vivo DCIS progression models identified BCL9 as a molecular driver of invasive progression
Conclusion: BCL9 is a molecular driver of DCIS invasive progression and may predispose to the development of basal like invasive breast cancers. As such, BCL9 has the potential to serve as a biomarker of high risk DCIS and as a therapeutic target for prevention of IDC.Citation Format: Behbod F, Elsarraj H, Hong Y, Valdez K, Chien J, Godwin A, Fields T. Expression profiling of in vivo DCIS progression models identified BCL9 as a molecular driver of invasive progression. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-05-05.
Source: Cancer Research - Category: Cancer & Oncology Authors: Behbod, F., Elsarraj, H., Hong, Y., Valdez, K., Chien, J., Godwin, A., Fields, T. Tags: Poster Session Abstracts Source Type: research
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Carcinoma in Situ | Colon Cancer | Colorectal Cancer | DCIS (Ductal Carcinoma in Situ) | Ductal Carcinoma | Epithelial Cancer | Genetics | HER2 | Lymphoma | Myeloma | Study